Dan Hicklin, Ph.D.
Dr. Dan Hicklin currently serves as an MPM Advisor and is Founder and CEO of Werewolf Therapeutics, an MPM portfolio company. Dan is an accomplished cancer researcher and biopharmaceutical executive with over three decades of oncology drug development experience. Most recently, Dan was Founder, President and CEO of Potenza Therapeutics (acquired by Astellas Pharma) and President and Chief Scientific Officer of CoStim Pharmaceuticals (acquired by Novartis). He also previously served as President of Trieza Therapeutics, on the board of Harpoon Therapeutics (NASDAQ: HARP), Tizona Therapeutics and Maverick Therapeutics, and on the scientific advisory board of Oncorus (NASDAQ: ONCR).
Prior to joining MPM, Dan held several positions at Merck Research Laboratories (formerly the Schering-Plough Research Institute prior to its acquisition by Merck), including leading their Biologics Strategy for Oncology and the Immuno-Modulation Discovery team. In these roles, he oversaw several oncology discovery and development projects including Merck’s immuno-oncology portfolio and the development of Keytruda® (pembrolizumab). Prior to joining Schering-Plough, Dan held several positions of increasing responsibility at ImClone Systems (acquired by Eli Lilly), including serving as Vice President of Experimental Therapeutics. His team at ImClone supported the development and FDA approval of the cancer treatment Erbitux® (cetuximab) and built a diversified portfolio of antibody therapeutics including Cyramza® (ramucirumab), Portrazza® (necitumumab), Lartruvo® (olaratumab) and other agents that were acquired by Eli Lilly.
Dan holds an M.S. and Ph.D. in Microbiology & Immunology from New York Medical College where he trained with Dr. Soldano Ferrone, and his B.S. from the University of Iowa.